An employee carries a branded paper bag inside the Delivery Hero AG headquarter offices in Berlin, Germany. Delivery Hero SE is facing pressure from several large shareholders to conduct a strategic review amid increasing consolidation in the food-delivery industry, people with knowledge of the matter said. Most Read from Bloomberg Investors including Hong Kong hedge fund Aspex Management, which is Delivery Hero’s second-biggest shareholder with a stake of more than 5%, are pushing management to consider ...

Core Viewpoint - Ramsay Health Care Limited has completed a strategic review regarding its majority shareholding in Ramsay Générale de Santé, with plans to execute one of the options considered and provide an update by February 2026 [1][2][3]. Group 1: Strategic Review - Ramsay Health Care Limited announced the completion of its strategic review with the assistance of Goldman Sachs [2]. - The Board and Management of Ramsay Health Care Limited are committed to executing one of the options from the strategic review [3]. - An update on the strategic options will be provided no later than the first half results publication in February 2026 [3]. Group 2: Company Overview - Ramsay Santé is the European leader in private hospitalization and primary care, employing 40,000 staff and 10,000 practitioners [4]. - The group serves 13 million patients annually across 492 facilities in five countries: France, Sweden, Norway, Denmark, and Italy [4]. - Ramsay Santé's mission encompasses a wide range of healthcare services, including medicine, surgery, obstetrics, rehabilitation, mental health, and primary care, focusing on innovation and equitable access to quality care [5].

Core Insights - Waldencast plc reported a 5.6% year-over-year increase in net revenue for Q2 2025, reaching $66.8 million, with an Adjusted EBITDA Margin of 5.0% [2][10] - The company experienced contrasting performances across its brands, with Obagi Medical showing strong growth while Milk Makeup faced challenges in international markets [2][6] - Waldencast has updated its FY 2025 guidance to reflect current trends and investments aimed at long-term growth [1][8] Obagi Medical - Obagi Medical achieved double-digit net revenue growth in Q3 2025, driven by strong e-commerce and international market performance [3][19] - The brand is preparing for the launch of Obagi Saypha®, which will double its addressable market in the U.S. [3][4] - The sale of the Obagi Japan trademark for $82.5 million and credit facility refinancing has strengthened the company's balance sheet [5][8] Milk Makeup - Milk Makeup's net revenue for Q3 2025 was $25.2 million, a decline of 20.1% compared to Q3 2024, despite an 8% increase in U.S. consumption [20][23] - The brand's growth in the U.S. was supported by retail expansion and successful product launches, but international performance was weaker [6][20] - Transformation initiatives are being implemented to revitalize the brand, including team restructuring and increased investment in international markets [7][8] Financial Performance - For H1 2025, Waldencast's net revenue increased by 0.5% year-over-year to $132.3 million, with a net loss of $185.2 million primarily due to impairment charges [13][14] - Adjusted EBITDA for H1 2025 was $7.7 million, representing a margin of 5.8%, down from 13.4% in H1 2024 [15][16] - Q3 2025 net revenue decreased by 3.4% year-over-year to $67.8 million, with Obagi Medical contributing $42.6 million and Milk Makeup $25.2 million [18][23] Strategic Initiatives - Waldencast is conducting a strategic review to maximize shareholder value, having retained Lazard as a financial advisor [8][9] - The company is focused on building a leading dermatological megabrand at the intersection of skincare and medical aesthetics [4][5] - Continued investments in innovation, digital capabilities, and new distribution channels are expected to drive sustainable growth [25][24]

Strategic Review Update - The Trust has been undergoing a strategic review since November 15, 2022, to maximize unitholder value, confirming no further growth in the US under the current platform [1] - The Board will pursue strategies to either sell and exit all current investments and return cash to unitholders or explore the sale or re-utilization of the Trust for another property or platform [1] Financial Performance - The Trust reported a net asset value (NAV) of $5.84 per Trust Unit (CAD $8.18), including disposition costs of assets held for sale [2] - For the three months ended September 30, 2025, net income was approximately $0.13 million, a decrease from $0.27 million in the previous quarter and $0.14 million in the same quarter last year [4] - For the nine months ended September 30, 2025, net income was approximately $0.57 million, compared to a loss of $0.29 million for the same period last year [4][6] Accretive Texas Property Refinancing - The Trust refinanced a $19.1 million fixed-rate mortgage with a new variable-rate mortgage, achieving a 166 basis point interest rate savings, equating to an interest rate of 6.59% [3] - The refinancing is expected to generate an annual AFFO savings of approximately $0.3 million or $0.04 per unit [3] Asset Dispositions - The Trust sold four of six wholly owned assets for gross proceeds of approximately $71.6 million, with net sale proceeds of about $28 million used for debt repayment [5] - The Trust provided seller financing of $4.0 million for its Florida property sale, generating a minimum 9% return that has escalated to 15% [5] - A joint venture property in Maryland was sold for $15.9 million, with the Trust receiving approximately $1.1 million from the sale [5]

Strategic Review Update - The Trust has been undergoing a strategic review since November 15, 2022, to maximize unitholder value, confirming no further growth in the US under the current platform [1][2] - The Board will pursue strategies to either sell and exit all current investments to return cash to unitholders or explore the sale or re-utilization of the Trust for another property or platform [1] Financial Performance - The Trust reported a net asset value (NAV) of $5.84 per Trust Unit (CAD $8.18), including disposition costs of assets held for sale [2] - For the three months ended September 30, 2025, net income was approximately $0.13 million, a decrease from $0.27 million in the previous quarter and $0.14 million in the same quarter last year [4][6] - For the nine months ended September 30, 2025, net income was approximately $0.57 million, compared to a loss of $0.29 million for the same period last year [4][6] Accretive Texas Property Refinancing - The Trust refinanced a $19.1 million fixed-rate mortgage with a new variable-rate mortgage, achieving a 166 basis point interest rate savings, equating to an interest rate of 6.59% [3] - The refinancing is expected to generate an annual AFFO savings of approximately $0.3 million or $0.04 per unit [3] Asset Sales and Transactions - The Trust sold four of six wholly owned assets for gross proceeds of approximately $71.6 million, with net sale proceeds of about $28 million used for debt repayment [5] - The Trust provided seller financing of $4.0 million for its Florida property sale, generating a minimum 9% return that has escalated to 15% [5] - A joint venture property in Maryland was sold for $15.9 million, with the Trust receiving approximately $1.1 million from the sale [5]

The owner of US and Canadian restaurant chains such as Cold Stone Creamery, Wetzel’s Pretzels and Mr. Sub said it’s undergoing a strategic review and may sell itself https://t.co/lwU0MEupB7 ...

Core Points - Waldencast plc has sold its rights to the "Obagi" trademark in Japan to Rohto Pharmaceutical Co., Ltd. for USD $82.5 million [1] - The transaction is part of Waldencast's strategy to improve its capital structure and maximize shareholder value [5][6] Financial Transactions - Rohto has been licensing the "Obagi" mark since 2002, and royalties from this arrangement accounted for 3% of net revenue for the Obagi Medical business for the fiscal year ended December 31, 2024 [2] - Waldencast has entered into a new credit agreement with Lumina Capital Management for a secured first-lien term loan facility of $225 million, aimed at improving liquidity and supporting brand growth [3][4] - Proceeds from the sale to Rohto will be used to repay a significant portion of the new loan facility, further deleveraging the company's balance sheet [4] Strategic Focus - The company is currently reviewing a range of strategic alternatives to enhance shareholder value, with the recent transactions reflecting this ongoing focus [5] - The CEO of Waldencast expressed that these transactions will substantially strengthen the company's balance sheet while exploring strategic options [6]

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Siemens said Wednesday it will transfer 30% of Siemens Healthineers shares to Siemens shareholders, giving up its controlling stake in the imaging and diagnostics company.  The move will allow Siemens, which now holds a 67% stake in Siemens Healthineers, to focus on its core technology portfolio with greater capital allocation flexibility, the German company said. “T ...

Core Insights - Bear Creek Mining Corporation reported its interim consolidated financial results for Q3 2025, highlighting operational challenges and financial losses [1][3][4] Financial Performance - Revenue for Q3 2025 was $22.5 million, with a comprehensive loss of $30.8 million, translating to a loss of $0.11 per share [4][21] - Adjusted earnings for the quarter were $(10.6) million, or $(0.04) per share, consistent with recent quarterly results [5][23] - Cash generated from operating activities was $(5.98) million, while cash used in investing activities was $(11.45) million, and financing activities generated $13.02 million [4][24] Production Highlights - The company produced 6,219 ounces of gold and 18,866 ounces of silver during Q3 2025 [5][6] - Total tonnes mined were 76,211, and tonnes processed were 79,457, with an average gold grade mined of 2.84 g/t [6][8] - Production was impacted by development deficits at the Mercedes mine due to operational challenges and ventilation issues at the Marianas deposit [3][9] Operational Challenges - The company faced significant operational challenges, including contractor underperformance and ground stability issues at the Marianas deposit, which hindered production [9][11] - A comprehensive recovery plan is being implemented to address these challenges, including transitioning to a replacement contractor [9][11] Strategic Initiatives - The company is actively conducting a Strategic Review to explore options for enhancing value, including potential asset sales or mergers [5][18] - Ongoing community support initiatives and environmental monitoring are being maintained at the Corani project [14][15] Debt Management - The company has deferred interest payments on certain debt agreements until December 31, 2025, and has issued a secured promissory note for up to $6.5 million for working capital [16][17] - As of September 30, 2025, the company had a net working capital deficiency of $113.1 million [25]

Q3 2025 Highlights - Production averaged 48 MBoe/D [12] - EBITDAX reached $140 million [12] - Capital expenditures decreased by over 30% from Q2, totaling $86.6 million [12] - Lease operating expenses (LOE) remained consistent with the first half of 2025 at $657 per Boe [12] - Liquidity increased by over $170 million due to extended debt maturities [12] Operational Updates - A second rig was added in mid-October [12] - A second successful simul-frac completion was implemented, resulting in an estimated savings of $25 million [12, 33] Financial Position (as of September 30, 2025) - Cash and cash equivalents stood at $165 million [36] - Total debt amounted to $12 billion [36] - Net debt was $1035 billion [36, 47] - Total liquidity, including RBL availability and cash, was $265 million [37] Hedging - 4Q25 average oil hedged is 177 MBO/d [39]